TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

TCR2 Therapeutics, a clinical-stage company focused on novel T cell therapies for cancer, announced that CFO Ian Somaiya will present an update on the company's progress at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM E.T. The presentation will be available through a live webcast on the company's investor website, with an archived replay accessible for 30 days. TCR2 is developing TRuC-T cells, which have shown superior anti-tumor activity in preclinical studies and are currently in clinical trials targeting multiple cancers.

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright 23^rd Annual Global Investment Conference on Monday, September 13^th at 7:00AM E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

 

FAQ

What is the date and time of TCRR's presentation at the H.C. Wainwright Conference?

TCRR's presentation is scheduled for September 13, 2021, at 7:00 AM E.T.

Who will present at the H.C. Wainwright Conference for TCRR?

Ian Somaiya, the Chief Financial Officer of TCRR, will present at the conference.

Where can I watch TCRR's presentation live?

The presentation will be available via live webcast on TCRR's investor website.

What is TCRR's lead product candidate in clinical trials?

TCRR's lead product candidate is gavo-cel, targeting solid tumors, currently in a Phase 1/2 clinical trial.

What types of cancer are TCRR's therapies targeting?

TCRR's therapies are targeting various cancers including non-small cell lung cancer, ovarian cancer, and acute lymphoblastic leukemia.